Table 5. Total (cfDNA) and relative mitochondrial cfDNA (cfmtDNA) content in our cohort of EC patients.
| Endometrial cancer (grade) | G1 | G2 | G3 |
|---|---|---|---|
| Total cfDNA ng/ml (Average concentration) ± SD | 645.6 ± 253.5 | 886.1 ± 336.7 | 846.3± 424.6 |
| Relative cfmtDNA (Average concentration) ± SD | 116.0 ± 28.2 | 121.0 ± 33.8 | 93.4 ± 15.7 |
| Total cfDNA ≥800 ng/ml (%) | 33.3 | 56.6 | 52.9 |
| Relative cfmtDNA <100 (%) | 44.4 | 68.9 | 72.2 |
| Hypertensive with total cfDNA ≥ 800 ng/ml (%) | 50.0 | 71.4 | 70.0 |
| Non-hypertensive with total cfDNA > 800 ng/ml (%) | 25 | 35.7 | 16.6 |
| Hypertensive with relative cfmtDNA <100 (%) | 25.0 | 71.4 | 100 |
| Non-hypertensive with relative mtcfDNA <100 (%) | 50 | 73.6 | 28.5 |
Cluster analysis of cfDNA content (total cfDNA and relative cfmtDNA) in G1, G2 and G3 EC sera and blood pressure level (hypertensive or non-hypertensive). SD: standard deviation.